Skip to main content

Table 2 Procedures and medication for clinical management of patients with ATTR-CM

From: Clinical manifestation, economic burden, and mortality in patients with transthyretin cardiac amyloidosis

  Pre-cohort entry date
(n = 175)
Post-cohort entry date
(n = 175)
Procedures, n (%)
Nerve conduction velocity test 11 (6.3) 30 (17.1)
Pacemaker 2 (1.1) 7 (4.0)
Implantable cardioverter defibrillator - 4 (2.3)
Surgery for spinal stenosis 3 (1.7) 2 (1.1)
Surgery for carpal tunnel syndrome 5 (2.9) 2 (1.1)
Liver transplant 1 (0.6)
Heart transplant 1 (0.6)
Tissue or mechanical valve implantation
Medication for clinical managements, n (%)
Diuretic 111 (63.4) 149 (85.1)
MRA 67 (38.3) 94 (53.7)
ARB 73 (41.7) 80 (45.7)
Statin 57 (32.6) 62 (35.4)
ACE inhibitor 29 (16.6) 38 (21.7)
Digitalis 25 (14.3) 28 (16.0)
Isosorbide dinitrate 12 (6.9) 20 (11.4)
Beta-blocker 17 (9.7) 12 (6.9)
Hydralazine 1 (0.6)
  1. ACE Angiotensin-converting enzyme, ARB Angiotensin receptor blocker, ATTR-CM Transthyretin amyloid cardiomyopathy, MRA Mineralocorticoid receptor antagonist, SD Standard deviation